Tuberous Sclerosis Complex
Approximately 78% of treated patients experienced at least 1 treatment-related adverse event.
The FDA has approved Afinitor Disperz for the adjunctive treatment of patients aged ≥2 years with TSC-associated partial-onset seizures.
Vigabatrin may be an effective option for patients with seizures due to tuberous sclerosis who do not respond to other anti-seizure treatments.
Adjunctive everolimus treatment has been found to significantly reduce frequency of treatment-resistant seizures in TSC.
The EXIST-3 trial is the first phase 3 study to evaluate the use of EVE for the adjunctive treatment of seizures in TSC.
The drug, which is indicated to treat certain types of cancer, is effective at reducing seizures in TSC when used as adjunctive therapy.
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study
- Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure